%0 Journal Article
%T Evaluation of the Efficacy of Topical Tetracycline in Enhancing the Effect of Narrow Band UVB against Vitiligo: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
%A Amir Kalafi
%A Farideh Jowkar
%J ISRN Dermatology
%D 2014
%R 10.1155/2014/472546
%X Background. Vitiligo is a pigmentary disorder characterized by depigmented macules due to absence of melanocytes. Increased levels of tumor necrosis factor alpha and interleukin-1 in the epidermis of lesions may play a role in keratinocyte apoptosis and less production of melanogenic cytokines. Tetracyclines reduce production of tumor necrosis factor alpha and interleukin-1. Objective. To evaluate the effect of topical tetracycline on vitiligo patients on phototherapy. Methods. Thirty cases of generalized stable vitiligo were chosen randomly and pigmentation of two assigned lesions on right and left sides (same size and location) was determined by vitiligo area severity index, and medication and placebo were randomly assigned to be applied twice daily on either right or left side, respectively. Images were taken of the lesions at the end of the 4th, 8th, and 12th weeks and pigmentations were compared to baseline using aforementioned index. The patients also took narrow band ultraviolet B two to three times a week. Results. Mean pigmentation, based on vitiligo area severity index, changed significantly from 90.1667 to 86.6667 ( ) and on placebo side from 89.6667 to 86.8333 ( ). There was no significant difference between medication and placebo sides in terms of pigmentation ( ). Conclusions. No significant difference in improving repigmentation between medication and placebo sides was seen. 1. Introduction Vitiligo is an acquired pigmentary disorder that presents with depigmented macules or patches that is due to absence of epidermal melanocytes. Men and women are equally affected. At least 30% of patients have positive family history of vitiligo [1]. In most cases, the disorder begins between 10 and 30 years [2]. Generalized form (symmetric involvement of more than 20% of body surface area) is the most common type. Antibodies to melanocytes are suggested as one possible cause of vitiligo [1]. In another hypothesis, expression of epidermal cytokines in lesions may be different when compared to normal skin. Keratinocyte-derived cytokines such as tumor necrosis factor-alpha (TNF-alpha) are thought to affect melanocyte survival and function [3]. There are increased levels of TNF-alpha and interleukin-1 (IL-1) in vitiligo lesions compared to normal skin. These cytokines seem to be able to destroy melanocytes [4]. Keratinocytes are involved in melanocyte homeostasis, so any change in keratinocytes may cause melanocyte dysfunction. High levels of TNF-alpha may play a role in keratinocyte apoptosis, which leads to less production of melanogenic cytokines and
%U http://www.hindawi.com/journals/isrn.dermatology/2014/472546/